Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Eiger Biopharmaceuticals (EIGRQ) has provided an update.
Eiger BioPharmaceuticals, Inc. and its subsidiaries, having filed for Chapter 11 bankruptcy in April 2024, recently submitted their Monthly Operating Reports for June 2024, cautioning investors against relying on these for investment decisions as they’re not GAAP compliant nor audited by independent accountants. The reports, prepared exclusively for meeting Bankruptcy Court requirements, may be adjusted in the future. Trading in the company’s securities is considered highly speculative, with substantial risks, and shareholders are warned they may face significant or total loss depending on the Chapter 11 case outcomes. The company also included forward-looking statements in its filings, advising that these are not guarantees of future performance and are subject to numerous risks and uncertainties.
See more data about EIGRQ stock on TipRanks’ Stock Analysis page.
